Glypican-3 (GPC3) is a member of glypican family encoded by GPC3 gene and anchored on cell surface by glycosylphosphatidylinositol, which is associated with cell growth, differentiation and migration. Recent researches revealed GPC3 is highly expressed on tumor cell such as melanoma, ovarian, yolk sca tumor, neuroblastoma and hepatocellular carcinoma, while restricted in normal tissues of adults, which confirms GPC3 as an attractive cellular target for cancer immunotherapy.
A Case Review: Treatment-Naïve Patient with Head and Neck Cancer.
Anti-GPC3 CAR-T Cell Therapy
GPC3 positive hepatocellular carcinoma (HCC) is one of most studied cancers for evaluations of GPC3 specific CAR-T therapy. Data indicates that about 70% of hepatocellular carcinoma patients have GPC3 expression on tumor cells. Both in vitro and in vivo studies indicate that GPC3-targeted CAR-T cells show significant cytotoxic effects on tumor cell when using CD28 and CD137 costimulatory domains. Third generation GPC3-targeted CAR-T cells like GPC3-28BBZ have been used in several Phase I clinical trials to evaluate safety and efficacy in patients with hepatocellular carcinoma. These studies have been registered and are being conducted (NCT02395250 and NCT02723942).
Creative Biolabs established several xenograft tumor models for studies of anti-GPC3 CAR-T therapy. Immunocompromised mice used for tumor model development are housed in pathogen-free condition and quarantined for one week before experiment. Animal experiments in Creative Biolabs are monitored by an approved Institutional Animal Care and Use Committee (IACUC).
Xenograft model of human hepatocellular carcinoma
This model is developed by subcutaneous injection of human hepatocellular tumor cell Huh-7 (or Hep-1, Hep3B) into mice on right flank and received GPC3-targeted CAR-T cells when tumor size meet criteria.
Xenograft model of lung squamous cell carcinoma
Cell NCI-H520 or SK-MES-1 expressing GPC3 are subcutaneously incubated into mice on right or left flank, and followed by CAR-T cell injection via tail vein.
In vivo Assay Parameters and Techniques
Creative Biolabs offers comprehensive services to test anti-GPC3 CAR-T therapy in preclinical trials. All tests are conduct by experienced technicians and strike to milestone of timeline.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
GLP-Compliant Preclinical Test
All our experiments are performed by well-trained and experienced technicians in a GLP-compliant and IACUC-regulated facility.
Technical team in Creative Biolabs has extensive knowledge and experience for evaluation of GPC3 specific CAR-T cell therapy. We provide different in vivo tumor models and analyzing assays for preclinical evaluation of adoptive T cell therapy.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE